Opportunity Information: Apply for RFA DK 13 028
Apply for RFA DK 13 028
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas (SBIR) (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Dec 4, 2013 and posted on Dec 4, 2013.
- Applicants must submit their applications by Mar 14, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,500,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas (SBIR) (R43/R44)" (Funding Opportunity Number RFA-DK-13-028) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding announcement designed to support small businesses working on new technologies that can move the field closer to a practical artificial pancreas. The central aim is to encourage research and development that improves or enables integrated, long-term systems capable of regulating blood glucose by automatically delivering insulin and potentially other pancreatic hormones. In plain terms, NIH is looking to fund small companies that can help make closed-loop diabetes management more accurate, reliable, durable, and usable in real-world settings for people with Type 1 diabetes.
This is a discretionary grant program under the SBIR mechanism, using the NIH R43/R44 phases. That structure generally aligns with early-stage feasibility work followed by more advanced development and validation, with Phase I (R43) often focused on proving that a concept can work and Phase II (R44) aimed at building and testing a more mature prototype or product candidate. While the source text does not list topic sub-areas in detail, the stated scope is clearly centered on innovative therapeutics and monitoring technologies that enable or improve glucose-responsive hormone delivery systems. This can include components that strengthen an artificial pancreas ecosystem, such as improved glucose monitoring performance, better control algorithms, safer and more precise delivery methods, longer-wear or more biocompatible sensors and infusion interfaces, or other enabling technologies that help integrate monitoring and delivery into a dependable closed-loop system.
The opportunity is administered by NIH within the portfolio associated with Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847). The activity category is listed under health (and tagged in the source data with food and nutrition/health), reflecting the programmatic focus on diabetes management and related biomedical technology development. The announcement specifically targets small business concerns as eligible applicants, which is consistent with SBIRs being intended to stimulate technological innovation in the private sector and help translate research ideas into products.
From a funding and timing standpoint, the FOA listed an estimated total funding amount of $2,500,000. The announcement was posted and created on December 4, 2013, with an original and current closing date of March 14, 2014, and an archive date of April 14, 2014, indicating the solicitation is historical and no longer open. There is no cost sharing or matching requirement, meaning applicants were not required to provide a matching contribution as a condition of the award.
Eligibility rules in the announcement emphasize that it is a U.S.-focused SBIR opportunity. Non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible either. However, the FOA notes that foreign components, as defined in the NIH Grants Policy Statement, may be allowed in some circumstances, which typically means certain limited project elements may be conducted abroad if well-justified and compliant with NIH policy, even though the applicant organization itself must be eligible and U.S.-based.
For applicants or readers seeking the full official details, the FOA provided an NIH guide link (http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-13-028.html). For access issues or technical problems with the posting, the listed support contact is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs)
What is the official title of this grant opportunity?
The opportunity is titled "Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas (SBIR) (R43/R44)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-DK-13-028.
Who is the sponsoring agency for this opportunity?
This funding announcement is administered by the National Institutes of Health (NIH).
What program or activity mechanism does this use?
This is an NIH Small Business Innovation Research (SBIR) funding announcement using the R43/R44 activity codes, which correspond to SBIR Phase I (R43) and SBIR Phase II (R44).
What is the main purpose of this SBIR FOA?
The central purpose is to support small businesses developing new therapeutics and monitoring technologies that move the field closer to a practical artificial pancreas, with an emphasis on integrated, long-term systems that regulate blood glucose through automated delivery of insulin and potentially other pancreatic hormones.
In practical terms, what kinds of projects is NIH trying to fund here?
Based on the stated scope, NIH is seeking innovations that make closed-loop Type 1 diabetes management more accurate, reliable, durable, and usable in real-world settings. This includes work that enables or improves glucose-responsive hormone delivery systems and their integration into dependable closed-loop systems.
Does the FOA specify topic sub-areas or a detailed list of research topics?
The provided information does not list detailed topic sub-areas. It does, however, clearly center on innovative therapeutics and monitoring technologies that enable or improve closed-loop (artificial pancreas) systems.
What are examples of technologies that appear to fit the scope described?
The description suggests relevance for components that strengthen an artificial pancreas ecosystem, such as improved glucose monitoring performance, better control algorithms, safer or more precise delivery methods, longer-wear or more biocompatible sensors and infusion interfaces, and other enabling technologies that support integration of monitoring and delivery into a dependable closed-loop system.
What is the grant type or assistance category?
This is described as a discretionary grant program under the SBIR mechanism.
What is the difference between R43 and R44 in this announcement?
As described, Phase I (R43) generally aligns with early-stage feasibility work to show a concept can work, and Phase II (R44) generally aligns with more advanced development and validation to build and test a more mature prototype or product candidate.
Who is eligible to apply?
The announcement targets small business concerns as eligible applicants, consistent with SBIR programs that are intended to stimulate private-sector technological innovation and help translate research ideas into products.
Are non-U.S. (foreign) institutions eligible to apply?
No. Non-U.S. (foreign) institutions are not eligible to apply for this opportunity.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible, as stated in the provided information.
Are any foreign activities allowed at all?
The information notes that foreign components (as defined in the NIH Grants Policy Statement) may be allowed in some circumstances. This generally means limited elements may be conducted abroad if justified and compliant with NIH policy, even though the applicant organization must be eligible and U.S.-based.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the estimated total funding amount listed for this FOA?
The estimated total funding amount listed is $2,500,000.
What CFDA number is associated with this opportunity?
The CFDA number provided is 93.847, within the portfolio associated with Diabetes, Digestive, and Kidney Diseases Extramural Research.
What general category does this opportunity fall under?
The activity category is listed under health (and tagged in the source data with food and nutrition/health), reflecting a focus on diabetes management and biomedical technology development.
When was this FOA posted?
The announcement was posted and created on December 4, 2013.
What was the application closing date?
The original and current closing date listed is March 14, 2014.
Is this grant opportunity still open?
No. The archive date is April 14, 2014, and the closing date was March 14, 2014, indicating the solicitation is historical and no longer open.
Where can someone find the official NIH FOA text?
The FOA provided the NIH guide link: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-13-028.html
Who should be contacted for technical issues with the posting or access problems?
The listed support contact is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more business programs for Business Consultants, Innovation Research Organizations, Business Innovation, Diabetes Research
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Fiscal Year 2014 Environmental Studies Program
Previous opportunity: The Palliative Care Research Cooperative (PCRC) Enhancing Sustainability and Building the Science of Palliative Care (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 13 028
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 13 028) also looked into and applied for these:
| Funding Opportunity |
|---|
| Lead Optimization and Pre Clinical Development of Therapeutic Candidates for Diseases of Interest to NIDDK (STTR (R41/R42)) Apply for PA 14 054 Funding Number: PA 14 054 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Lead Optimization and Pre Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (SBIR (R43/R44)) Apply for PA 14 055 Funding Number: PA 14 055 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Small Business Technology Transfer Research (STTR) to Develop New Diagnostic, Monitoring and Therapeutics Technologies for the Complications of Type 1 Diabetes (T1D) STTR (R41/R42) Apply for PA 14 059 Funding Number: PA 14 059 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Small Business Innovation Research (SBIR) to Develop New Diagnostic, Monitoring and Therapeutics Technologies for the Complications of Type 1 Diabetes (T1D) (SBIR (R43/R44)) Apply for PA 14 058 Funding Number: PA 14 058 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Subjects From Selected Type I Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 14 064 Funding Number: PAR 14 064 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Biosamples From Selected Type 1 Diabetes Clinical Studies (DP3) Apply for PAR 14 065 Funding Number: PAR 14 065 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Cystic Fibrosis Research and Translation Core Center (P30) Apply for RFA DK 13 007 Funding Number: RFA DK 13 007 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Systems for Health Apply for RFA 641 14 00002 Funding Number: RFA 641 14 00002 Agency: Ghana USAID Accra Category: Food and Nutrition Health Funding Amount: $68,000,000 |
| Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) (U01) Apply for RFA DK 14 501 Funding Number: RFA DK 14 501 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $400,000 |
| Limited Competition Continuation of the Type 2 Diabetes in Adolescents and Youth (TODAY) Study (U01) Apply for RFA DK 14 502 Funding Number: RFA DK 14 502 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $10,000,000 |
| Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) Apply for RFA DK 14 003 Funding Number: RFA DK 14 003 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $300,000 |
| Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) Apply for RFA DK 14 503 Funding Number: RFA DK 14 503 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $2,500,000 |
| Reagents for Glucagon and Incretin Research (R41/R42) Apply for PA 14 204 Funding Number: PA 14 204 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Reagents for Glucagon and Incretin Research (R43/R44) Apply for RFA DK 14 008 Funding Number: RFA DK 14 008 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Clinical, Physiological and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (DP3) Apply for RFA DK 14 014 Funding Number: RFA DK 14 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Impact Award Closed Loop Technologies Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3) Apply for RFA DK 14 015 Funding Number: RFA DK 14 015 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Nutrition Obesity Research Centers (NORCs) (P30) Apply for RFA DK 14 002 Funding Number: RFA DK 14 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Silvio O. Conte Digestive Diseases Research Core Centers (P30) Apply for RFA DK 14 012 Funding Number: RFA DK 14 012 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $750,000 |
| Increasing the Quality and Efficiency of Clinical Trials (R18) Apply for RFA FD 14 017 Funding Number: RFA FD 14 017 Agency: Food Drug Administration Category: Food and Nutrition Health Funding Amount: $7,500,000 |
| U.S. India Bilateral Collaborative Research Partnerships (CRP) on Diabetes Research (R21) Apply for RFA DK 14 006 Funding Number: RFA DK 14 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $275,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 13 028", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.